Edgewood Oncology is a technology company.
Edgewood Oncology has raised $20.0M across 1 funding round.
Edgewood Oncology has raised $20.0M in total across 1 funding round.
Edgewood Oncology has raised $20.0M in total across 1 funding round.
Edgewood Oncology's investors include 5AM Ventures, Alta Partners, Kiersten Stead.
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a novel small molecule multi-kinase inhibitor that synergistically targets master regulators of cancer to induce programmed cell death.[1][2] It serves patients with hematologic malignancies like relapsed/refractory acute myeloid leukemia (R/R AML) and high-risk myelodysplastic syndrome (HR-MDS), as well as genetically-defined solid tumors such as GATA3-mutant breast cancer, addressing unmet needs in these hard-to-treat populations with promising Phase 1 safety and efficacy data.[1][2][5] The company emerged from stealth in March 2024 with $20 million in Series A financing from Alta Partners to advance Phase 2 trials, adopting a virtual model for efficient development.[2]
Edgewood Oncology was formed in 2024 to advance BTX-A51 based on its synergistic mechanism, favorable safety profile, and anti-tumor activity observed in Phase 1 trials for AML and solid tumors.[2] Led by CEO David N. Cook, Ph.D., a biotech veteran, the leadership team comprises seasoned executives focused on precision medicine for patients lacking effective options.[2] The company launched from stealth on March 25, 2024, securing $20 million in Series A funding from Alta Partners to initiate Phase 2 studies in R/R AML (combined with azacitidine) and GATA3-mutant breast cancer in Q2 2024.[2]
Edgewood rides the wave of precision oncology, targeting genetically-defined cancers amid rising demand for therapies beyond standard chemo in AML (high relapse rates) and GATA3-mutant breast cancer (poor prognosis).[1][5] Timing aligns with post-2024 biotech funding recovery and advances in multi-kinase inhibitors, leveraging Phase 1 data from prior studies to fast-track Phase 2.[2] Market forces like unmet needs in R/R hematologic malignancies (limited options post-venetoclax/azacitidine) and breast cancer resistance favor its profile; Edgewood influences the ecosystem by validating BTX-A51's potential in combinations, potentially expanding to broader solid tumors.[2][5]
Edgewood's near-term catalysts include Phase 2a data readouts in R/R AML (with azacitidine) and GATA3-mutant breast cancer, building on Phase 1 CRis and safety—key to de-risking and attracting follow-on investment.[2][5] Trends like AI-driven patient stratification and combo therapies will shape progress, positioning BTX-A51 for partnerships or expansion if efficacy holds. Influence may grow via proof-of-concept in precision subsets, delivering on its founding promise for unmet needs in oncology.[1][2]
Edgewood Oncology has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $20.0M Series A | 5AM Ventures, Alta Partners, Kiersten Stead |